



Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

January 27, 2025

NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:

Guggenheim Securities SMID Cap Biotech Conference, New York

Fireside Chat

Wednesday, February 5, 2025, at 1:30 pm ET

A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit <https://www.tourmalinebio.com> or follow us on [LinkedIn](#) or [X](#).

Media Contact

Scient PR

Sarah Mishek

SMishek@ScientPR.com

Investor Contact

Meru Advisors

Lee M. Stern

lsfern@meruadvisors.com



Source: Tourmaline Bio, Inc.